We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $178.41, moving +1.49% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.85%. On the other hand, the Dow registered a gain of 1.36%, and the technology-centric Nasdaq increased by 0.72%.
Shares of the world's biggest maker of health care products have appreciated by 0.79% over the course of the past month, underperforming the Medical sector's gain of 6.01%, and the S&P 500's gain of 2.38%.
The investment community will be closely monitoring the performance of Johnson & Johnson in its forthcoming earnings report. The company is scheduled to release its earnings on October 14, 2025. The company is predicted to post an EPS of $2.78, indicating a 14.88% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.74 billion, reflecting a 5.63% rise from the equivalent quarter last year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $10.86 per share and revenue of $93.41 billion. These results would represent year-over-year changes of +8.82% and +5.17%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. As of now, Johnson & Johnson holds a Zacks Rank of #2 (Buy).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 16.19. This indicates a premium in contrast to its industry's Forward P/E of 14.14.
One should further note that JNJ currently holds a PEG ratio of 2.24. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $178.41, moving +1.49% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.85%. On the other hand, the Dow registered a gain of 1.36%, and the technology-centric Nasdaq increased by 0.72%.
Shares of the world's biggest maker of health care products have appreciated by 0.79% over the course of the past month, underperforming the Medical sector's gain of 6.01%, and the S&P 500's gain of 2.38%.
The investment community will be closely monitoring the performance of Johnson & Johnson in its forthcoming earnings report. The company is scheduled to release its earnings on October 14, 2025. The company is predicted to post an EPS of $2.78, indicating a 14.88% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.74 billion, reflecting a 5.63% rise from the equivalent quarter last year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $10.86 per share and revenue of $93.41 billion. These results would represent year-over-year changes of +8.82% and +5.17%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. As of now, Johnson & Johnson holds a Zacks Rank of #2 (Buy).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 16.19. This indicates a premium in contrast to its industry's Forward P/E of 14.14.
One should further note that JNJ currently holds a PEG ratio of 2.24. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 159, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.